Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ECLECTIC: EstroTEP and Circulating Biomarkers to Determine the Optimal Second Line Therapy for ER-positive HER2-negative Metastatic Breast Cancer Patients

NCT06195709 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT06195709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06195709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ECLECTIC: EstroTEP and Circulating Biomarkers to Determine the Optimal Second Line Therapy for ER-positive HER2-negative Metastatic Breast Cancer Patients
Lead sponsor
Institut Curie
Phase
Phase 3
Overall status
Recruiting
Start date
May 27, 2024
Completion date
September 27, 2030
Enrollment
300 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

breast carcinoma